ACRV
Income statement / Annual
Last year (2023), Acrivon Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Acrivon Therapeutics, Inc. Common Stock's net income was -$60.39 M.
See Acrivon Therapeutics, Inc. Common Stock’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$536,000.00 |
$1.10 M |
$832,000.00 |
$13,000.00 |
| Gross Profit |
-$536,000.00 |
-$1.10 M |
-$832,000.00 |
-$13,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$45.49 M
|
$23.95 M
|
$13.72 M
|
$1.87 M
|
| General & Administrative
Expenses |
$21.08 M
|
$8.71 M
|
$2.47 M
|
$1.30 M
|
| Selling & Marketing
Expenses |
$134,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$21.21 M
|
$8.71 M
|
$2.47 M
|
$1.30 M
|
| Other Expenses |
$0.00 |
$1.49 M |
-$59,000.00 |
-$2.14 M |
| Operating Expenses |
$66.70 M |
$32.66 M |
$16.18 M |
$3.17 M |
| Cost And Expenses |
$67.24 M |
$32.66 M |
$16.18 M |
$3.17 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$1.49 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$536,000.00
|
$1.10 M
|
$832,000.00
|
$13,000.00
|
| EBITDA |
-$66.70 M
|
-$32.66 M
|
-$16.15 M
|
-$3.16 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.85 M
|
$1.49 M
|
-$59,000.00
|
-$2.14 M
|
| Income Before Tax |
-$60.39 M |
-$31.17 M |
-$16.24 M |
-$5.31 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$1.00 |
-$1.49 M |
-$199,558.00 |
-$193,297.00 |
| Net Income |
-$60.39 M |
-$29.68 M |
-$16.24 M |
-$5.31 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
| EPS |
-2.74 |
-1.35 |
-0.78 |
-0.25 |
| EPS Diluted |
-2.74 |
-1.35 |
-0.78 |
-0.25 |
| Weighted Average Shares
Out |
$22.08 M
|
$21.92 M
|
$20.86 M
|
$20.86 M
|
| Weighted Average Shares
Out Diluted |
$22.08 M
|
$21.92 M
|
$20.86 M
|
$20.86 M
|
| Link |
|
|
|
|
